ANVS
Companies
Nyse American
Annovis Bio, Inc.
Health Care
$2.70
-$2.33 (-46.32%)
Price Chart
Overview
About ANVS
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
Market Cap
$68.9M
Volume
771.7K
Avg. Volume
909.5K
P/E Ratio
-0.7016575
Dividend Yield
0.00%
Employees
7.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.41
High Correlation
Volatility
High (1.00)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
High Sensitivity
GDP Growth
High Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, ANVS shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$68.9M
Volume771.7K
P/E Ratio-0.70
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
March 22, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025